LC Fund VI, L.P. 3

Accession 0001209191-18-047866

CIK 0001411690other

Filed

Aug 20, 8:00 PM ET

Accepted

Aug 21, 7:50 PM ET

Size

16.4 KB

Accession

0001209191-18-047866

Form 3

Period: 2018-08-21

10% Owner

Holdings

Series D Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (6,443,565 underlying)
Series D Convertible Preferred Stock Warrants (Right to Buy)
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.41From: 2016-03-04Exp: 2026-03-04→ Series D Convertible Preferred Stock (11,263,624 underlying)
Series D-1 Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (27,305,708 underlying)
Series C Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (8,545,184 underlying)

10% Owner

Holdings

Series C Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (8,545,184 underlying)
Series D Convertible Preferred Stock Warrants (Right to Buy)
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.41From: 2016-03-04Exp: 2026-03-04→ Series D Convertible Preferred Stock (11,263,624 underlying)
Series D Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (6,443,565 underlying)
Series D-1 Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (27,305,708 underlying)

10% Owner

Holdings

Series C Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (8,545,184 underlying)
Series D-1 Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (27,305,708 underlying)
Series D Convertible Preferred Stock
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.00→ Common Stock (6,443,565 underlying)
Series D Convertible Preferred Stock Warrants (Right to Buy)
(indirect: By entities affiliated with LC Fund VI, L.P.)
Exercise: $0.41From: 2016-03-04Exp: 2026-03-04→ Series D Convertible Preferred Stock (11,263,624 underlying)

Footnotes (5)

[F1]The convertible preferred stock is convertible at any time at the holder's election and automatically converts upon the consummation of a qualified public offering of the registrant. There is no expiration date for any series of preferred stock.
[F2]The shares are held as follows: 8,203,376 shares held by LC Fund VI, L.P. ("LC Fund") and 341,808 shares held by LC Parallel Fund VI, L.P. ("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.
[F3]The shares are held as follows: 6,143,224 shares held by LC Fund and 300,341 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.
[F4]The shares are held as follows: 3,924,722 shares held by LC Fund, 241,948 shares held by Parallel Fund and 23,139,038 shares held by LC Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital, a limited liability Chinese company ("Legend Capital"). The Reporting Person is ultimately controlled and managed by Legend Capital.
[F5]The warrants are held as follows: warrant to purchase 10,738,615 shares held by LC Fund and warrant to purchase 525,009 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.

Documents

2 files

BioNano Genomics, Inc

CIK 0001411690

Entity typeother

IncorporatedCayman Islands